Tokyo Tape
Sign in
← CellSeed

Annual report

7776.TEDINET S100QIL1
Period2022-01-01 → 2022-12-31
Filed2023-03-31
StandardJapan GAAP
ConsolidatedNo
Data checks9 of 12 passed
Key figures · 110
MetricValuePeriodScopeSource row
Revenue¥126m2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥162m2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥199m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥276m2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥1.0bn2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥743m2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥864m2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥754m2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥866m2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥887m2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥745m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥729m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥786m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥787m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥141m2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥141m2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥759m2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥909m2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income (owners)−¥915m2021-01-01 → 2021-12-31StandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥784m2020-01-01 → 2020-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥782m2019-01-01 → 2019-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)¥130m2018-01-01 → 2018-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income−¥760m2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥913m2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥768m2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥783m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income¥130m2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.5bnat 2022-12-31StandaloneAssets
Total assets¥1.4bnat 2021-12-31StandaloneAssets
Total assets¥1.4bnat 2021-12-31StandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.5bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.5bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.6bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.6bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥366mat 2022-12-31StandaloneLiabilities
Total liabilities¥364mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.0bnat 2021-12-31StandaloneNet assets
Net assets / equity¥1.0bnat 2021-12-31StandaloneNet assets (5-year summary)
Net assets / equity¥1.6bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥1.5bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.3bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.4bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.4bnat 2018-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.4bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.1bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥847mat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥1.1bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥847mat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥931mat 2021-12-31StandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.5bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.1bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.1bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥718m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥817m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥701m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥578m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥307m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥62m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥110m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥13m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥133m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥882m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥397m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥721m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥25m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-36.312022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.182021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.082021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-55.312020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-54.192020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.62019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.682019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥11.352018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥11.382018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥11.272018-01-01 → 2018-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥11.32018-01-01 → 2018-12-31dStandaloneDiluted earnings per share (5-year summary)
Net assets per share¥47.26at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥56.44at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥57.43at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥93.85at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥95.7at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥102.24at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥103.88at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥121.19at 2018-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥122.78at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio74.8%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio72.0%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio72.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio83.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.5%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.1%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.3%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.5%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.3%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE9.8%2018-01-01 → 2018-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued24,422,619at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,759,419at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued16,008,319at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued12,981,819at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,459,419at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees30at 2022-12-31StandaloneNumber of employees
Employees44at 2021-12-31StandaloneNumber of employees
Employees40at 2020-12-31dStandaloneNumber of employees
Employees40at 2019-12-31dStandaloneNumber of employees
Employees39at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 21
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2022-01-01 → 2022-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥1.3bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥190m
Cell Sheet Regenerative Medicinereportable segmentemployeesat 2022-12-3119 pure
Cell Sheet Regenerative Medicinereportable segmentrevenue2022-01-01 → 2022-12-31¥10m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2022-01-01 → 2022-12-31¥10m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2022-12-31¥82m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2022-01-01 → 2022-12-31−¥463m
Laboratory Consumables And Equipmentreportable segmentcapex2022-01-01 → 2022-12-31¥563,000
Laboratory Consumables And Equipmentreportable segmentdepreciation2022-01-01 → 2022-12-31¥8m
Laboratory Consumables And Equipmentreportable segmentemployeesat 2022-12-317 pure
Laboratory Consumables And Equipmentreportable segmentrevenue2022-01-01 → 2022-12-31¥116m
Laboratory Consumables And Equipmentreportable segmentrevenue external2022-01-01 → 2022-12-31¥116m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2022-12-31¥196m
Laboratory Consumables And Equipmentreportable segmentsegment profit2022-01-01 → 2022-12-31−¥90m
—segment totalcapex2022-01-01 → 2022-12-31¥563,000
—segment totaldepreciation2022-01-01 → 2022-12-31¥8m
—segment totalrevenue2022-01-01 → 2022-12-31¥126m
—segment totalrevenue external2022-01-01 → 2022-12-31¥126m
—segment totalsegment assetsat 2022-12-31¥277m
—segment totalsegment profit2022-01-01 → 2022-12-31−¥553m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 895
ItemContextValueUnit
Cash and cash equivalents (5-year summary)CurrentYearInstant_NonConsolidatedMember1072210000JPY
Number of employeesPrior4YearInstant_NonConsolidatedMember39
Number of employeesPrior3YearInstant_NonConsolidatedMember40
Number of employeesPrior2YearInstant_NonConsolidatedMember40
Number of employeesPrior1YearInstant_NonConsolidatedMember44
Number of employeesCurrentYearInstant_NonConsolidatedMember30
Average number of temporary workersPrior4YearInstant_NonConsolidatedMember－
Average number of temporary workersPrior3YearInstant_NonConsolidatedMember－
Average number of temporary workersPrior2YearInstant_NonConsolidatedMember－
Average number of temporary workersPrior1YearInstant_NonConsolidatedMember－
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember－
Total shareholder returnPrior4YearInstant_NonConsolidatedMember1.446
Total shareholder returnPrior3YearInstant_NonConsolidatedMember1.115
Total shareholder returnPrior2YearInstant_NonConsolidatedMember0.535
Total shareholder returnPrior1YearInstant_NonConsolidatedMember0.398
Total shareholder returnCurrentYearInstant_NonConsolidatedMember0.364
Total return on share price indexPrior4YearInstant_NonConsolidatedMember0.840
Total return on share price indexPrior3YearInstant_NonConsolidatedMember0.992
Total return on share price indexPrior2YearInstant_NonConsolidatedMember1.066
Total return on share price indexPrior1YearInstant_NonConsolidatedMember1.202
Total return on share price indexCurrentYearInstant_NonConsolidatedMember1.172
Number of employeesCurrentYearInstant_NonConsolidatedMember30
Average age years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember44.7
Average length of service years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember4.7
Average annual salary information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember5734322JPY
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember7
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember19
Number of employeesCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember4
Number of employeesCurrentYearInstant_NonConsolidatedMember30
Research and development expenses research and development activitiesCurrentYearDuration444759000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember35914000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember408844000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration4054000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember24422619
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember27659419
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant24422619
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant27659419
Number of shares constituting one unitCurrentYearInstant_OrdinaryShareMember100
Number of shareholders national and local governmentsCurrentYearInstant_OrdinaryShareMember1
Number of shareholders financial institutionsCurrentYearInstant_OrdinaryShareMember1
Number of shareholders financial service providersCurrentYearInstant_OrdinaryShareMember27
Number of shareholders other corporationsCurrentYearInstant_OrdinaryShareMember78
Number of shareholders foreign investors other than individualsCurrentYearInstant_OrdinaryShareMember34
Number of shareholders foreign individual investorsCurrentYearInstant_OrdinaryShareMember32
Number of shareholders individuals and othersCurrentYearInstant_OrdinaryShareMember14357
Number of shareholders totalCurrentYearInstant_OrdinaryShareMember14530
Number of shares held number of units national and local governmentsCurrentYearInstant_OrdinaryShareMember10
Number of shares held number of units financial institutionsCurrentYearInstant_OrdinaryShareMember1502
Number of shares held number of units financial service providersCurrentYearInstant_OrdinaryShareMember22962
Number of shares held number of units other corporationsCurrentYearInstant_OrdinaryShareMember7315

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 9 of 12 passed
balance sheet identitynon_consolidated 2021-12-31pass rounding
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-12-31mismatch
statement vs summary · net assetsnon_consolidated 2021-12-31mismatch
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31mismatch
statement vs summary · total assetsnon_consolidated 2022-12-31pass